SEC Form 4 · accession 0001209191-15-077349
AGIOS PHARMACEUTICALS, INC. · AGIO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
David P Schenkein
Officer — Chief Executive Officer · Director
Period of report
Oct 27, 2015
Accepted (ET)
Oct 30, 2015 · 10:52 am EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001439222
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common stockF2 | Oct 27, 2015 | M | 4,000 | $31.64 | A | 236,272 | I | See footnote |
| Common stockF4,F2 | Oct 27, 2015 | S | 4,000 | $80.26 | D | 232,272 | I | See footnote |
| Common stockF5 | holding | — | — | — | 79,082 | I | See footnote |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock option (right to buy)F6 | $31.64 | Oct 27, 2015 | M | 4,000 | D | — | Mar 4, 2024 | Common stock | 4,000 | 867,320 | D |
Explanation of responses
- F1This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- F2Shares held by David P. Schenkein 2004 Revocable Trust, of which the reporting person is trustee and beneficiary.
- F3This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- F4The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $80.00 to $80.44. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- F5Shares held by Amy P. Schenkein 2004 Revocable Trust, of which the reporting person's spouse is trustee and beneficiary.
- F6This option was granted on March 5, 2014. The shares underlying this option vest as to 25% of the underlying shares on March 5, 2015, with the remaining 75% vesting in 36 equal monthly installments thereafter.